Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib

Genomic tumour profiling informs targeted treatment options. Entrectinib is a tyrosine kinase inhibitor with efficacy in NTRK fusion‐positive (‐fp) solid tumours and ROS1‐fp non‐small cell lung cancer. FoundationOne® Liquid CDx (F1L CDx), a non‐invasive in  vitro next‐generation sequencing (NGS)‐bas...

Descripción completa

Detalles Bibliográficos
Autores principales: Dziadziuszko, Rafal, Hung, Tiffany, Wang, Kun, Choeurng, Voleak, Drilon, Alexander, Doebele, Robert C., Barlesi, Fabrice, Wu, Charlie, Dennis, Lucas, Skoletsky, Joel, Woodhouse, Ryan, Li, Meijuan, Chang, Ching‐Wei, Simmons, Brian, Riehl, Todd, Wilson, Timothy R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120896/
https://www.ncbi.nlm.nih.gov/pubmed/35338679
http://dx.doi.org/10.1002/1878-0261.13214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120896/
https://www.ncbi.nlm.nih.gov/pubmed/35338679
http://dx.doi.org/10.1002/1878-0261.13214

Ejemplares similares